PROVIVA THERAPEUTICS
Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.
PROVIVA THERAPEUTICS
Industry:
Biotechnology Life Science Medical Therapeutics
Status:
Active
Total Funding:
0
Investors List
JMCR Partners
JMCR Partners investment in Seed Round - Proviva Therapeutics
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund investment in Seed Round - Proviva Therapeutics
More informations about "Proviva Therapeutics"
Proviva Therapeutics Company Profile 2024: Valuation, โฆ
Proviva Therapeutics General Information Description. Developer of pharmaceutical technology platform intended for anti-tumor immunity. The company develops a prodrug technology platform that can achieve specific โฆSee details»
Proviva Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Proviva Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 1 literature, Disease Domain:Neoplasms, Technology Platform:Fusion โฆSee details»
Proviva Therapeutics - Viva BioInnovator
Viva BioInnovator. No. 50, Lane 63, Faraday Road, Zhangjiang High-Tech Park, Shanghai, 201203, China.See details»
Proviva Therapeutics (Hong Kong) - PitchBook
Jun 28, 2019 Information on valuation, funding, cap tables, investors, and executives for Proviva Therapeutics (Hong Kong). Use the PitchBook Platform to explore the full profile.See details»
Proviva Therapeutics - Funding, Financials, Valuation & Investors
Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... How โฆSee details»
CN114450297 - Drug Targets, Indications, Patents - Synapse
CN114450297, Initially developed by Proviva Therapeutics ๏ผHong Kong๏ผ Limited, Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms,Immune System โฆSee details»
Proviva Therapeutics - Products, Competitors, Financials, โฆ
Proviva Therapeutics seals $18m Series A round Biotech firm Proviva Therapeutics has completed its $18 million Series A financing round participated by Lapam Capital, Ennovation โฆSee details»
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with ...
Lead Organization. Lead OrganizationProviva Therapeutics, Inc. Trial IDs. Primary IDPTX-912-001; Secondary IDsNCI-2024-03600; ClinicalTrials.gov IDNCT06190886; Share this clinical โฆSee details»
Proviva Therapeutics - Updates, News, Events, Signals & Triggers
Proviva Therapeutics Ltd. has made progress in cancer treatment research, specifically with PTX-912, which shows promise in reducing tumor growth in murine melanoma models. This โฆSee details»
Proviva Therapeutics Asset Profile - Preqin
Established in 2019 and based in Shanghai, China, Proviva Therapeutics is a pharmaceutical company that focuses on developing innovative antitumor biologics. In March 2024, it raised a โฆSee details»
Proviva Therapeutics - VentureRadar
858 Therapeutics USA Privately Held 858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in โฆSee details»
PTX-912 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Primary objectives: 1. To evaluate the safety and tolerability of PTX-912 in patients with locally advanced or metastatic solid tumors. 2. To determine the maximum โฆSee details»
PD 1-proIL-2v - Proviva Therapeutics - AdisInsight
PD 1-proIL-2v is fusion protein therapeutic being developed by Proviva Therapeutics for the treatment of Solid tumours. PD-1-proIL-2v is a novel anti-PD-1 and PD 1-proIL-2v - Proviva โฆSee details»
Provivaโs PTX-912 reduces tumor growth in murine melanoma model
Apr 15, 2024 Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are โฆSee details»
Proviva Therapeutics - Crunchbase
Symbol Therapeutics is a drug discovery company developing a novel immunoregulatory therapeutic protein. Proviva Therapeutics and Symbol Therapeutics share similar industries โฆSee details»
Program Guide โ ASCO Meeting Program Guide - American โฆ
Proviva Therapeutics. Background: HD IL-2 was approved by FDA for metastatic melanoma (mM) and renal cell carcinoma (mRCC) but the treatment is associated with severe toxicities. PD-1 โฆSee details»
PTX-912 in Solid Tumor and Metastatic Cancer and Advanced
Dec 19, 2023 November 4, 2024 updated by: Proviva Therapeutics, Inc. A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of โฆSee details»
Series A - Proviva Therapeutics - 2024-03-06 - Crunchbase
Mar 6, 2024 Proviva Therapeutics raised $18000000 on 2024-03-06 in Series A. Start Free Trial . Chrome ExtensionSee details»
Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on ...
May 29, 2024 Proviva Therapeutics, Shanghai, China. View all articles by this author. Notes. Abstract Disclosures. Funding Information. Proviva Therapeutics. Metrics & Citations Metrics. โฆSee details»